John Paul Waymack
Technik-/Wissenschafts-/F&E-Leiter bei MOLECULIN BIOTECH, INC.
Aktive Positionen von John Paul Waymack
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MOLECULIN BIOTECH, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Pam-Bio Ltd.
 Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von John Paul Waymack
Ehemalige bekannte Positionen von John Paul Waymack
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PURPLE BIOTECH LTD | Vorsitzender | 12.08.1968 | 01.07.2019 |
| Technik-/Wissenschafts-/F&E-Leiter | 12.08.1968 | 09.01.2020 | |
| Gründer | 12.08.1968 | 09.01.2020 | |
| University of Medicine & Dentistry of New Jersey | Corporate Officer/Principal | - | - |
| The United States Army Medical Service Corps | Corporate Officer/Principal | - | - |
Kitov Pharmaceuticals Ltd.
 Kitov Pharmaceuticals Ltd. Medical DistributorsDistribution Services Part of Purple Biotech Ltd., Kitov Pharmaceuticals Ltd. is committed to providing cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance. The Israeli company's proposed drug, CM24, attenuates/block tumor growth and metastatic processes, while their novel small molecule, NT219, targets both IRS1/2 and STAT3. CM24 is a monoclonal antibody blocking CEACAM1, and NT219 targets the novel cancer drug resistance pathways. Kitov Pharmaceuticals was acquired by Mainrom Line Logistics Ltd. on July 18, 2013. | Vorsitzender | - | - |
| Technik-/Wissenschafts-/F&E-Leiter | - | - | |
| The University of Texas at Austin | Corporate Officer/Principal | - | - |
Statistik
International
| Vereinigte Staaten | 5 |
| Israel | 4 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 3 |
| Chairman | 2 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
| Distribution Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PURPLE BIOTECH LTD | Health Technology |
| MOLECULIN BIOTECH, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
| The United States Army Medical Service Corps | |
Kitov Pharmaceuticals Ltd.
Kitov Pharmaceuticals Ltd. Medical DistributorsDistribution Services Part of Purple Biotech Ltd., Kitov Pharmaceuticals Ltd. is committed to providing cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance. The Israeli company's proposed drug, CM24, attenuates/block tumor growth and metastatic processes, while their novel small molecule, NT219, targets both IRS1/2 and STAT3. CM24 is a monoclonal antibody blocking CEACAM1, and NT219 targets the novel cancer drug resistance pathways. Kitov Pharmaceuticals was acquired by Mainrom Line Logistics Ltd. on July 18, 2013. | Distribution Services |
Pam-Bio Ltd.
Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | Health Technology |
- Börse
- Insiders
- John Paul Waymack
- Erfahrung
